{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:14:18Z","timestamp":1795209258063,"version":"4.10.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008368","name":"Gigtforeningen","doi-asserted-by":"publisher","award":["A4190"],"award-info":[{"award-number":["A4190"]}],"id":[{"id":"10.13039\/100008368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lymphocyte activation gene-3 (LAG-3) inhibits T cell activation and interferes with the immune response by binding to MHC-II. As antigen presentation is central in rheumatoid arthritis (RA) pathogenesis, we studied aspects of LAG-3 as a serological marker and mediator in the pathogenesis of RA. Since Galectin-3 (Gal-3) is described as an additional binding partner for LAG-3, we also aimed to study the functional importance of this interaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma levels of soluble (s) LAG-3 were measured in early RA patients (eRA,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200999) at baseline and after 12\u00a0months on a treat-to-target protocol, in self-reportedly healthy controls (HC,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932), and in paired plasma and synovial fluid (SF) from chronic RA patients (cRA,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200938). Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) were examined for LAG-3 expression by flow cytometry. The binding and functional outcomes of LAG-3 and Gal-3 interaction were assessed with surface plasmon resonance (SPR) and in cell cultures using rh-LAG3, an antagonistic LAG-3 antibody and a Gal-3 inhibitor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline sLAG-3 in the plasma was increased in eRA compared to HC and remained significantly elevated throughout 12\u00a0months of treatment. A high level of sLAG-3 at baseline was associated with the presence of IgM-RF and anti-CCP as well as radiographic progression. In cRA, sLAG-3 was significantly increased in SF compared with plasma, and LAG-3 was primarily expressed by activated T cells in SFMCs compared to PBMCs. Adding recombinant human LAG-3 to RA cell cultures resulted in decreased cytokine secretion, whereas blocking LAG-3 with an antagonistic antibody resulted in increased cytokine secretion. By SPR, we found a dose-dependent binding between LAG-3 and Gal-3. However, inhibiting Gal-3 in cultures did not further change cytokine production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>sLAG-3 in the plasma and synovial fluid is increased in both early and chronic RA patients, particularly in the inflamed joint. High levels of sLAG-3 are associated with autoantibody seropositivity and radiographic progression in eRA, and LAG-3 plays a biologically active role in cRA by decreasing inflammatory cytokine production. This functional outcome is not affected by Gal-3 interference. Our results suggest that LAG-3 is a faceted regulator of inflammation in early and chronic RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-023-03073-z","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T02:01:48Z","timestamp":1686103308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis"],"prefix":"10.1186","volume":"25","author":[{"given":"Janni Maria","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida Solh\u00f8j","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e6cilie","family":"Skej\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Juul-Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"H\u00f8rslev-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Stengaard-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne Kuno","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen-Margrethe","family":"Hauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene","family":"Hvid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stinne","family":"Greisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"10055","key":"3073_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"2","key":"3073_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrrheum.2016.200","volume":"13","author":"AI Catrina","year":"2017","unstructured":"Catrina AI, Svensson CI, Malmstrom V, Schett G, Klareskog L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol. 2017;13(2):79\u201386.","journal-title":"Nat Rev Rheumatol"},{"issue":"8\u20139","key":"3073_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00251-017-0987-5","volume":"69","author":"ASB Kampstra","year":"2017","unstructured":"Kampstra ASB, Toes REM. HLA class II and rheumatoid arthritis: the bumpy road of revelation. Immunogenetics. 2017;69(8\u20139):597\u2013603.","journal-title":"Immunogenetics"},{"issue":"2","key":"3073_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.coi.2009.01.010","volume":"21","author":"A Crawford","year":"2009","unstructured":"Crawford A, Wherry EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol. 2009;21(2):179\u201386.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"3073_CR5","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/eji.201344413","volume":"45","author":"ME Turnis","year":"2015","unstructured":"Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. 2015;45(7):1892\u2013905.","journal-title":"Eur J Immunol"},{"issue":"1","key":"3073_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"issue":"5","key":"3073_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"2","key":"3073_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","volume":"26","author":"N Li","year":"2007","unstructured":"Li N, Wang Y, Forbes K, Vignali KM, Heale BS, Saftig P, et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J. 2007;26(2):494\u2013504.","journal-title":"EMBO J"},{"issue":"9","key":"3073_CR9","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","volume":"180","author":"B Liang","year":"2008","unstructured":"Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916\u201326.","journal-title":"J Immunol"},{"issue":"12","key":"3073_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","volume":"19","author":"T Maruhashi","year":"2018","unstructured":"Maruhashi T, Okazaki IM, Sugiura D, Takahashi S, Maeda TK, Shimizu K, et al. LAG-3 inhibits the activation of CD4(+) T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol. 2018;19(12):1415\u201326.","journal-title":"Nat Immunol"},{"issue":"8","key":"3073_CR11","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.4049\/jimmunol.161.8.4058","volume":"161","author":"S Hannier","year":"1998","unstructured":"Hannier S, Tournier M, Bismuth G, Triebel F. CD3\/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3\/TCR signaling. J Immunol (Baltimore, MD: 1950). 1998;161(8):4058\u201365.","journal-title":"J Immunol (Baltimore, MD: 1950)"},{"issue":"2","key":"3073_CR12","doi-asserted-by":"publisher","first-page":"e000482","DOI":"10.1136\/esmoopen-2018-000482","volume":"4","author":"HC Puhr","year":"2019","unstructured":"Puhr HC, Ilhan-Mutlu A. New emerging targets in cancer immunotherapy: the role of LAG3. ESMO Open. 2019;4(2):e000482.","journal-title":"ESMO Open"},{"issue":"4","key":"3073_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Can Res. 2012;72(4):917\u201327.","journal-title":"Can Res"},{"issue":"1","key":"3073_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","volume":"15","author":"LT Nguyen","year":"2015","unstructured":"Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3\u2013potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45\u201356.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"3073_CR15","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","volume":"186","author":"P Hemon","year":"2011","unstructured":"Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol (Baltimore, Md: 1950). 2011;186(9):5173\u201383.","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"5","key":"3073_CR16","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2016.148965","volume":"102","author":"M Shapiro","year":"2017","unstructured":"Shapiro M, Herishanu Y, Katz BZ, Dezorella N, Sun C, Kay S, et al. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. Haematologica. 2017;102(5):874\u201382.","journal-title":"Haematologica"},{"issue":"1","key":"3073_CR17","doi-asserted-by":"publisher","first-page":"e86551","DOI":"10.1371\/journal.pone.0086551","volume":"9","author":"EI Sega","year":"2014","unstructured":"Sega EI, Leveson-Gower DB, Florek M, Schneidawind D, Luong RH, Negrin RS. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS one. 2014;9(1):e86551.","journal-title":"PLoS one"},{"issue":"11","key":"3073_CR18","doi-asserted-by":"publisher","first-page":"e109080","DOI":"10.1371\/journal.pone.0109080","volume":"9","author":"NM Durham","year":"2014","unstructured":"Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, et al. Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS one. 2014;9(11):e109080.","journal-title":"PLoS one"},{"key":"3073_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jim.2017.04.006","volume":"447","author":"S Anvari","year":"2017","unstructured":"Anvari S, Grimbergen A, Davis CM, Makedonas G. Protein transport inhibitors downregulate the expression of LAG-3 on regulatory T cells. J Immunol Methods. 2017;447:47\u201351.","journal-title":"J Immunol Methods"},{"issue":"4","key":"3073_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","volume":"3","author":"T Kouo","year":"2015","unstructured":"Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015;3(4):412\u201323.","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"3073_CR21","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","volume":"74","author":"F Xu","year":"2014","unstructured":"Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Can Res. 2014;74(13):3418\u201328.","journal-title":"Can Res"},{"issue":"1\u20132","key":"3073_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","volume":"176","author":"J Wang","year":"2019","unstructured":"Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1\u20132):334-47.e12.","journal-title":"Cell"},{"issue":"6","key":"3073_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/sji.12619","volume":"86","author":"SF Issa","year":"2017","unstructured":"Issa SF, Christensen AF, Lindegaard HM, Hetland ML, H\u00f8rslev-Petersen K, Stengaard-Pedersen K, et al. Galectin-3 is persistently increased in early rheumatoid arthritis (RA) and associates with anti-CCP seropositivity and MRI bone lesions, while early fibrosis markers correlate with disease activity. Scand J Immunol. 2017;86(6):471\u20138.","journal-title":"Scand J Immunol"},{"key":"3073_CR24","doi-asserted-by":"crossref","unstructured":"Nielsen MA, K\u00f8ster D, Greisen S, Troldborg A, Stengaard-Pedersen K, Junker P, et al. Increased synovial galectin-3 induce inflammatory fibroblast activation and osteoclastogenesis in patients with rheumatoid arthritis. Scand J Rheumatol.\u00a0Scand J Rheumatol. 2023;52(1):33\u201341.","DOI":"10.1080\/03009742.2021.1992860"},{"issue":"26","key":"3073_CR25","doi-asserted-by":"publisher","first-page":"21751","DOI":"10.1074\/jbc.C112.358002","volume":"287","author":"A Lepur","year":"2012","unstructured":"Lepur A, Salomonsson E, Nilsson UJ, Leffler H. Ligand induced galectin-3 protein self-association. J Biol Chem. 2012;287(26):21751\u20136.","journal-title":"J Biol Chem"},{"issue":"2","key":"3073_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.176.2.327","volume":"176","author":"E Baixeras","year":"1992","unstructured":"Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176(2):327\u201337.","journal-title":"J Exp Med"},{"issue":"4","key":"3073_CR27","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","volume":"73","author":"K Horslev-Petersen","year":"2014","unstructured":"Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2014;73(4):654\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3073_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/2193-1801-2-263","volume":"2","author":"TW Kragstrup","year":"2013","unstructured":"Kragstrup TW, Vorup-Jensen T, Deleuran B, Hvid M. A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-animal IgG antibodies in plasma from arthritis patients. Springerplus. 2013;2(1):263.","journal-title":"Springerplus"},{"issue":"2","key":"3073_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cei.12577","volume":"180","author":"TW Kragstrup","year":"2015","unstructured":"Kragstrup TW, Andersen T, Holm C, Schiottz-Christensen B, Jurik AG, Hvid M, et al. Toll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activity. Clin Exp Immunol. 2015;180(2):233\u201342.","journal-title":"Clin Exp Immunol"},{"issue":"33","key":"3073_CR30","doi-asserted-by":"publisher","first-page":"16963","DOI":"10.1074\/jbc.M116.732222","volume":"291","author":"MR Jensen","year":"2016","unstructured":"Jensen MR, Bajic G, Zhang X, Laustsen AK, Kolds\u00f8 H, Skeby KK, et al. Structural basis for simvastatin competitive antagonism of complement receptor 3. J Biol Chem. 2016;291(33):16963\u201376.","journal-title":"J Biol Chem"},{"issue":"1","key":"3073_CR31","doi-asserted-by":"publisher","first-page":"1810488","DOI":"10.1080\/19420862.2020.1810488","volume":"12","author":"SK Chaturvedi","year":"2020","unstructured":"Chaturvedi SK, Parupudi A, Juul-Madsen K, Nguyen A, Vorup-Jensen T, Dragulin-Otto S, et al. Measuring aggregates, self-association, and weak interactions in concentrated therapeutic antibody solutions. MAbs. 2020;12(1):1810488.","journal-title":"MAbs"},{"issue":"3","key":"3073_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymeth.2012.12.007","volume":"59","author":"H Zhao","year":"2013","unstructured":"Zhao H, Gorshkova II, Fu GL, Schuck P. A comparison of binding surfaces for SPR biosensing using an antibody-antigen system and affinity distribution analysis. Methods. 2013;59(3):328\u201335.","journal-title":"Methods"},{"key":"3073_CR33","doi-asserted-by":"publisher","first-page":"563258","DOI":"10.3389\/fimmu.2020.563258","volume":"11","author":"Y Qi","year":"2020","unstructured":"Qi Y, Chen L, Liu Q, Kong X, Fang Y, Wang J. Research progress concerning dual blockade of lymphocyte-activation gene 3 and programmed death-1\/programmed death-1 ligand-1 Blockade in cancer immunotherapy: preclinical and clinical evidence of this potentially more effective immunotherapy strategy. Front Immunol. 2020;11:563258.","journal-title":"Front Immunol"},{"issue":"2","key":"3073_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/jem.20100466","volume":"208","author":"T Okazaki","year":"2011","unstructured":"Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208(2):395\u2013407.","journal-title":"J Exp Med"},{"issue":"1","key":"3073_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/art.37755","volume":"65","author":"T Isozaki","year":"2013","unstructured":"Isozaki T, Rabquer BJ, Ruth JH, Haines GK 3rd, Koch AE. ADAM-10 is overexpressed in rheumatoid arthritis synovial tissue and mediates angiogenesis. Arthritis Rheum. 2013;65(1):98\u2013108.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3073_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13075-018-1657-1","volume":"20","author":"S Ishii","year":"2018","unstructured":"Ishii S, Isozaki T, Furuya H, Takeuchi H, Tsubokura Y, Inagaki K, et al. ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion. Arthritis Res Ther. 2018;20(1):159.","journal-title":"Arthritis Res Ther"},{"issue":"7562","key":"3073_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"523","author":"EF McKinney","year":"2015","unstructured":"McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612\u20136.","journal-title":"Nature"},{"issue":"12","key":"3073_CR38","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s41590-018-0257-1","volume":"19","author":"Y Lui","year":"2018","unstructured":"Lui Y, Davis SJ. LAG-3: a very singular immune checkpoint. Nat Immunol. 2018;19(12):1278\u20139.","journal-title":"Nat Immunol"},{"issue":"6","key":"3073_CR39","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.4049\/jimmunol.1401025","volume":"193","author":"J Bae","year":"2014","unstructured":"Bae J, Lee SJ, Park CG, Lee YS, Chun T. Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling. J Immunol. 2014;193(6):3101\u201312.","journal-title":"J Immunol"},{"key":"3073_CR40","doi-asserted-by":"publisher","first-page":"915890","DOI":"10.3389\/fimmu.2022.915890","volume":"13","author":"MA Nielsen","year":"2022","unstructured":"Nielsen MA, Juul-Madsen K, Stegmayr J, Gao C, Mehta AY, Greisen SR, et al. Galectin-3 decreases 4\u20131BBL bioactivity by crosslinking soluble and membrane expressed 4\u20131BB. Front Immunol. 2022;13:915890.","journal-title":"Front Immunol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03073-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03073-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03073-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T02:04:55Z","timestamp":1686103495000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03073-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3073"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03073-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies were approved by the Danish Medical Agency (2612\u20133393), the Danish Data Protection Agency (2007\u201341-0072 and 2011\u201341-6863), and the Regional Ethics Committee (VEK-20070008, 1\u201310-72\u2013291-12 and 1\u201310-72\u2013189-13), and the subjects\u2019 written consents were obtained according to the Declaration of Helsinki. HC control samples were obtained from the Aarhus University Hospitals Blood Bank. Signed consent was not necessary by Danish law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}